Cerus Corp chief legal officer Chrystal Jensen sells $71,597 in stock
Chrystal Jensen, Chief Legal Officer at Cerus Corp (NASDAQ:CERS), sold 24,329 shares of common stock totaling $71,597 on June 30, 2026. These sales were not discretionary but rather to cover tax withholding obligations and brokerage fees related to restricted stock unit vesting. Following these transactions, Jensen directly holds 966,657 shares of CERUS CORP.
Cerus Corp chief legal officer Chrystal Jensen sells $71,597 in stock
Chrystal Jensen, Chief Legal Officer of Cerus Corp, sold 24,329 shares of common stock for $71,597 on June 30, 2026. These sales were primarily to cover tax withholding obligations related to restricted stock unit vesting, rather than a discretionary sale. The company recently reported better-than-expected first-quarter 2026 earnings and secured a new debt facility to reduce interest expenses.
Cerus COO Vivek Jayaraman disposes of $124,658 in stock for taxes
Cerus COO Vivek Jayaraman sold $124,658 worth of company stock to cover tax withholding obligations associated with the vesting of restricted stock units. This transaction, occurring on June 30, 2026, involved the sale of 42,359 shares at an average price of $2.9429. Additionally, Jayaraman received a grant of 554,529 Restricted Stock Units and 369,686 performance rights, with vesting schedules tied to continued service and company stock performance, respectively.
Cerus CFO Kevin Green sells $99,105 in CERS shares
Cerus CFO Kevin Green sold 33,676 shares of CERS stock for $99,105 on June 30, 2026, under a pre-arranged trading plan to cover tax obligations from restricted stock unit vesting, not as a discretionary sale. Following these transactions, Green directly holds 1,062,188 shares. The company, with a $627 million valuation, is currently unprofitable and its stock is trading near a 52-week high after a 103% return in the past year.
Cerus Corp chief legal officer Chrystal Jensen sells $71,597 in stock
Chrystal Jensen, Chief Legal Officer at Cerus Corp (NASDAQ: CERS), sold 24,329 shares of common stock for $71,597 on June 30, 2026. These sales were not discretionary but made to cover tax withholding obligations and brokerage fees related to restricted stock unit vesting. The company's stock is currently trading near its 52-week high, with recent first-quarter earnings surpassing expectations and a new debt facility secured for up to $110 million.
Cerus (CERS) CFO logs tax-related share sale and new stock grant
Cerus Corp's CFO, Kevin Dennis Green, reported a non-discretionary sale of 33,676 shares at a weighted average price of $2.94 to cover tax withholding and brokerage fees related to restricted stock unit vesting. On the same date, he also received a grant of 63,600 shares at no cost. Following these transactions, Green directly holds 1,095,864 shares of Cerus common stock.
Cerus Corp chief legal officer Chrystal Jensen sells $71,597 in stock
Cerus Corp's Chief Legal Officer, Chrystal Jensen, sold 24,329 shares of common stock for $71,597 to cover tax obligations related to restricted stock unit vesting. This transaction is not considered a discretionary sale, and Jensen still holds 966,657 shares. The sale occurred while CERS stock is near its 52-week high, and the company recently surpassed Q1 2026 earnings expectations and secured a new debt facility to reduce interest expenses.
Cerus (CERS) COO granted RSUs, performance rights and sells shares
Cerus Corp's COO, Vivek K. Jayaraman, received significant equity grants including 554,529 shares of common stock and 369,686 performance rights, with vesting contingent on continued service and the company's stock performance. Concurrently, he sold 42,359 shares worth approximately $125,000 under a pre-set Rule 10b5-1 plan to cover tax withholding and fees, not as a discretionary sale. Following these transactions, Jayaraman holds over 2.2 million common shares and all his performance rights.
Cerus (NASDAQ: CERS) CLO reports Rule 10b5-1 tax sale and 55,000-share grant
Cerus Corp's Chief Legal Officer, Chrystal Jensen, reported two common stock transactions on June 30, 2026. Jensen sold 24,329 shares at a weighted average price of $2.9429 to cover tax withholding obligations and brokerage fees related to vesting restricted stock units under a Rule 10b5-1 plan. On the same day, she also received a grant of 55,000 shares at no cost, increasing her direct holdings to 990,986 shares.
CERUS (CERS) CEO Greenman logs tax-related share sale and 192,500-share grant
CERUS (CERS) President and CEO William Mariner Greenman reported a tax-related sale of 101,919 shares to cover withholding and brokerage fees, alongside receiving a grant of 192,500 shares at no cost. These transactions, conducted under a Rule 10b5-1 plan, resulted in a net increase in his direct ownership to 5,154,955 shares. The sale was characterized as non-discretionary and compensation-related rather than a change in market outlook.
Cerus Corp (CERS) Institutional Confidence
Cerus Corp (CERS) has an institutional shareholding score of 7.00, placing it 79th out of 203 in the Healthcare Equipment & Supplies industry. Institutional investors hold 73.57% of the shares, a slight decrease of 1.81% quarter-over-quarter. Catherine Wood is the largest institutional shareholder, holding 9.57% of outstanding shares.
Cerus Corp (CERS) Financial Health: Profitability & Balance Sheet Analysis
Cerus Corp (CERS) currently holds a financial score of 8.05, placing it 48th out of 203 in the Healthcare Equipment & Supplies industry, indicating stable financial health and high operating efficiency. The company recently reported a quarterly revenue of $59.89 million, marking a 22.60% year-over-year increase, and its net profit surged by 78.75% year-over-year. The analysis highlights its strong quality of earnings, operational efficiency, and growth potential, though specific financial data for cash and other key metrics are not yet disclosed.
Cerus Corp (CERS) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Cerus Corp (CERS), detailing its current price momentum, support and resistance levels, and signals from various technical indicators and moving averages. The stock is currently trading between resistance at $3.08 and support at $2.36, indicating potential for range-bound swing trading. Technical indicators show a mixed signal, while moving averages overwhelmingly suggest a "Buy" signal.
Cerus to Showcase New Evidence, Innovation and Global Experience with the INTERCEPT Blood System at the 39th International ISBT Congress
Cerus Corporation announced its participation in the 39th International ISBT Congress in Kuala Lumpur, Malaysia, from June 20-24, 2026. The company will host a symposium and present abstracts highlighting the INTERCEPT Blood System's role in enhancing blood safety, operational efficiency, and patient care. Presentations will cover growing evidence, real-world experiences from blood centers across Asia, and innovations like the LED-based INT200 illuminator and extended platelet shelf-life.
Cerus Corp (CERS) Earnings Forecast: Future EPS & Revenue Growth Estimates
Cerus Corp (CERS) has an earnings forecast score of 8.67, ranking 16th in the Healthcare Equipment & Supplies industry, with an average analyst price target of $5.00. Based on ratings from 3 analysts, the stock has a "Buy" trend. The expected revenue for the next quarter is $60.93 million, and the EPS for the previous quarter was -$0.01, with a forecast of -$0.02 for the upcoming quarter.
Cerus Corp (CERS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Cerus Corp (CERS) based on its business segments and regional contributions. For the fiscal year 2025, Product revenue accounted for 88.17% ($206.13M) and Government Contract revenue for 11.83% ($27.66M). Geographically, the United States contributed 65.18% ($152.39M) of total revenue, with Other Countries making up 25.75% ($60.21M), and France specifically 9.07% ($21.20M).
Cerus Corp (CERS) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Cerus Corp (CERS), highlighting major shareholders and institutional holdings. It provides a breakdown of shareholder types, institutional shareholding over several quarters, and a list of key shareholder activities with changes in their holdings. The data reveals that ARK Investment Management LLC, BlackRock Institutional Trust Company, N.A., and Baker Bros. Advisors LP are among the top shareholders.
Cerus Corp (CERS) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Cerus Corp (CERS)'s dividend and stock split history, noting that the company has distributed $0.00 in dividends over the past five years and has no recorded stock splits. It also includes current stock performance metrics such as a +8.50% gain during market hours and a market cap of 514.94M.
Cerus takes INTERCEPT blood system data to global transfusion congress
Cerus Corporation (Nasdaq: CERS) announced its participation in the 39th International ISBT Congress in Kuala Lumpur, Malaysia, from June 20-24, 2026. The company will host a symposium and present abstracts highlighting the INTERCEPT Blood System's effectiveness in enhancing blood safety, improving operational efficiency, and addressing bacterial contamination risks in platelet components. Presentations will cover innovations like reduced processing times with the LED-based INT200 illuminator and extended platelet shelf-life, with real-world examples from Asia.
Cerus Corporation (CERS) Closes New Debt Facility of Up to $110M
Cerus Corporation has secured a new debt facility of up to $110 million with MidCap Financial, combining a five-year term loan with an asset-backed revolving loan. This refinancing is expected to reduce annual cash interest expenses by up to $3.5 million and lowers the outstanding term loan balance by approximately $30 million. The company aims to strengthen its financial foundation through extended maturities and reduced borrowing costs, deferring amortization for 48 months.
Cerus Corporation (CERS) Closes New Debt Facility of Up to $110M
Cerus Corporation (CERS) recently closed a new debt facility with MidCap Financial, securing up to $110 million through a five-year term loan and an asset-backed revolving loan. This refinancing is expected to reduce annual cash interest expenses by up to $3.5 million and decrease its outstanding term loan balance by approximately $30 million. The company utilized initial proceeds and cash to retire an existing $65 million loan and gained access to additional funding and flexibility with a new revolving facility.
5 Best Genomics Stocks to Buy According to Analysts
This article identifies Cerus Corporation (NASDAQ: CERS) as a top genomics stock to buy, with analysts projecting a 66.05% upside potential. Cerus recently secured a new debt facility of up to $110 million, which is expected to cut annual cash interest expenses by up to $3.5 million and strengthen its financial foundation. The company specializes in the research, development, and manufacturing of biomedical and surgical products.
Cerus Corporation (NASDAQ:CERS) Sees Significant Decrease in Short Interest
Cerus Corporation (NASDAQ:CERS) experienced a significant 41.9% decrease in short interest in May, bringing the total shorted shares to 10.77 million and the short-interest ratio to 4.2 days. Analyst sentiment is mixed but improving, with recent upgrades to "Buy" from BTIG Research and Wall Street Zen, while insiders have recently sold shares. The company reported better-than-expected quarterly results, with a smaller loss and higher revenue than forecasted.
Cerus Corp director Eric Bjerkholt sells $53,180 in stock By Investing.com
Cerus Corp director Eric Bjerkholt sold 20,454 shares of common stock for approximately $53,180. This sale follows Cerus stock's 89% return over the past year, though InvestingPro analysis suggests it remains undervalued. Bjerkholt now directly owns 261,679 shares, and the company recently exceeded Q1 2026 earnings expectations and secured a new $110 million debt facility.
Director Eric Bjerkholt Sells 20,454 Shares of Cerus Corp (CERS)
Director Eric Bjerkholt sold 20,454 shares of Cerus Corp (CERS) on June 9, 2026, reducing his holding to 261,679 shares. This transaction is part of a pattern of 14 insider sells versus 1 insider buy over the past year for the biomedical company. Shares were trading at $2.60, making the stock modestly overvalued according to its GF Value of $2.23.
Cerus Corp director Eric Bjerkholt sells $53,180 in stock
Cerus Corp director Eric Bjerkholt sold 20,454 shares of common stock for $53,180, reducing his direct ownership to 261,679 shares. This sale follows a year of significant stock performance for Cerus, with an 89% return, despite an InvestingPro analysis suggesting the stock is undervalued. The company recently reported strong first-quarter earnings and secured a $110 million debt facility expected to reduce interest expenses.
Cerus Corp (CERS) director sells 20,454 common shares in open-market trade
Cerus Corp director Eric Bjerkholt sold 20,454 shares of common stock at $2.60 per share in an open-market transaction. Following this sale, Bjerkholt directly owns 261,679 shares of the company's common stock. The transaction represents a net sale of $53,180 and was reported via a Form 4 filing with the SEC.
Cerus Corp director Eric Bjerkholt sells $53,180 in stock
Cerus Corp director Eric Bjerkholt sold 20,454 shares of common stock for approximately $53,180 on June 9, 2026. This sale follows an 89% return for Cerus stock over the past year, although InvestingPro analysis suggests it remains undervalued. The company recently reported strong Q1 2026 earnings and secured a $110 million debt facility expected to reduce annual cash interest expenses.
$110M refinancing expected to save Cerus up to $3.5M a year
Cerus Corporation has secured a new debt facility of up to $110 million with MidCap Financial, comprising a 5-year term loan and an asset-backed revolving loan. This refinancing is projected to reduce the company's annual cash interest expense by as much as $3.5 million. The initial proceeds were used to retire Cerus' existing $65 million term loan, providing greater financial flexibility and supporting future growth.
Cerus Refinances Credit Facilities: $65 Million Term Loan and $30 Million Revolver With MidCap
Cerus has successfully refinanced its credit facilities with MidCap, entering into new agreements on June 5, 2026. This refinancing includes a secured term loan facility of up to $65 million and a secured revolving credit facility of $30 million, expandable to $45 million. The company anticipates that this updated financial structure will improve liquidity, support working capital, and better align covenants with its current operational needs.
Cerus (NASDAQ: CERS) refinances $65M term loan and $30M revolver
Cerus Corporation has refinanced and expanded its debt facilities with new secured credit agreements. The company secured a term loan facility of up to $65 million, with an initial draw of $35 million, and a revolving credit facility of $30 million, which can be increased by $15 million. These agreements feature floating interest rates tied to Term SOFR and are secured by substantially all of Cerus's assets, subject to financial covenants.
Cerus secures $110 million debt facility with MidCap Financial
Cerus Corporation has secured a new debt facility of up to $110 million with MidCap Financial, comprising a 5-year term loan and an asset-backed revolving loan. This refinancing is expected to reduce Cerus's annual cash interest expense by up to $3.5 million and has allowed the company to retire its existing $65 million term loan. The blood technology company reported strong first-quarter earnings for 2026, exceeding revenue and EPS expectations.
Cerus Corporation Closes New Debt Facility of Up to $110 Million
Cerus Corporation has secured a new debt facility of up to $110 million with MidCap Financial, comprising a 5-year term loan and an asset-backed revolving loan. This refinancing is expected to reduce annual cash interest expenses by up to $3.5 million and enhances the company's financial flexibility. The initial proceeds were used to retire existing debt, positioning Cerus for sustainable growth and execution of long-term strategic goals.
Cerus (NASDAQ: CERS) holders back equity plan, board and auditors
Cerus Corporation shareholders approved an amendment to the 2024 Equity Incentive Plan, increasing common stock available for issuance by 10,000,000 shares. Stockholders also re-elected William M. Greenman and Ann Lucena to the board until the 2029 Annual Meeting, approved executive compensation on an advisory basis, and ratified Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2026. These decisions were made during the company's 2026 Annual Meeting of Stockholders.
Cerus COO Vivek Jayaraman sells $50,001 in company stock
Vivek Jayaraman, COO of Cerus Corp (NASDAQ:CERS), sold 16,667 shares of company stock worth $50,001 on May 29, 2026, as part of a pre-arranged trading plan. This transaction occurred after Cerus shares surged over 104% in the past year. The company recently reported better-than-expected Q1 2026 earnings, with EPS and revenue exceeding analyst forecasts.
Cerus COO Vivek Jayaraman sells $50,001 in company stock By Investing.com
Cerus COO Vivek Jayaraman sold 16,667 shares of CERUS CORP (NASDAQ:CERS) stock for $50,001 at $3.00 per share, executed under a 10b5-1 trading plan. Despite the sale, Jayaraman still holds over 1.6 million shares, and the company's stock has seen a significant surge over the past year, though InvestingPro suggests it remains undervalued. Cerus also reported strong first-quarter 2026 earnings, exceeding analyst expectations for both EPS and revenue.
Cerus (CERS) director Jami Nachtsheim awarded 60,000 RSUs, lifting holdings to 268,362 shares
Cerus director Jami K. Nachtsheim was awarded 60,000 Restricted Stock Units (RSUs) as part of the company's 2024 Equity Incentive Plan, increasing her direct holdings to 268,362 shares. These RSUs were granted at no cash cost and vest on the earlier of one year from the grant date or the day before the next annual stockholder meeting, contingent on her continuous service. This transaction is classified as routine equity compensation for a director.
60,000 RSU award lifts Cerus (CERS) director holdings to 192,386
Cerus Corp (CERS) director Shan Hua received a grant of 60,000 restricted stock units (RSUs) under the company’s 2024 Equity Incentive Plan. This award increases her total holdings to 192,386 shares of common stock. The RSUs vest on the earlier of the first anniversary of the grant date or the day before the next annual stockholder meeting, contingent on continuous service.
Cerus (NASDAQ: CERS) COO executes 10b5-1 sale of 16,667 shares at $3
Cerus Corp's Chief Operating Officer, Vivek K. Jayaraman, sold 16,667 shares of common stock at $3.00 per share on May 29, 2026. This transaction was executed as an open-market sale under a pre-arranged Rule 10b5-1 trading plan. Following the sale, Jayaraman directly owns 1,656,707 shares of Cerus common stock.
Cerus COO Vivek Jayaraman sells $50,001 in company stock
Vivek K. Jayaraman, COO of CERUS CORP, sold 16,667 shares of common stock for $50,001. This transaction, executed under a 10b5-1 plan, occurred as CERUS shares saw a significant surge over the past year. Following the sale, Jayaraman still holds over 1.6 million shares directly.
Cerus (NASDAQ: CERS) director granted 60,000 RSUs under 2024 equity plan
Cerus Corp (NASDAQ: CERS) director Ann Lucena was granted 60,000 restricted stock units (RSUs) under the company's 2024 Equity Incentive Plan. These RSUs, which represent a contingent right to receive one share each, bring her total direct holdings to 232,284 shares. The RSUs will vest on the earlier of the first anniversary of the grant date or the day before the next annual stockholder meeting, conditional on her continuous service.
Cerus (NASDAQ: CERS) director receives 60,000 RSUs equity award
Cerus director Frank Witney was granted 60,000 Restricted Stock Units (RSUs) as an equity award under the company's 2024 Equity Incentive Plan. These RSUs represent a contingent right to receive one share of common stock each and will vest on the earlier of the first anniversary of the grant date or the day before the next annual stockholders' meeting, provided Witney maintains continuous service. Following this grant, Witney directly holds 340,059 shares of Cerus common stock.
Cerus (CERS) director Gregory Dean granted 60,000 RSUs in equity award
Cerus Corp. director Gregory Dean A. was granted 60,000 restricted stock units (RSUs) under the company's 2024 Equity Incentive Plan. These RSUs convert into shares upon vesting, which occurs on the earlier of the first anniversary of the grant or the day before the next annual stockholder meeting, provided he remains in service. Following this award, Dean directly holds 146,725 shares of Cerus common stock.
Cerus (CERS) director receives 60,000 RSUs under 2024 equity plan
Cerus Corp (CERS) director Eric Bjerkholt was granted 60,000 Restricted Stock Units (RSUs) under the company's 2024 Equity Incentive Plan. These RSUs were awarded at no cash cost and vest on the earlier of the first anniversary of the grant date or the day before the next annual stockholder meeting, provided continuous service to the company. Following this grant, Bjerkholt directly holds 282,133 shares of Cerus common stock.
CERS - Cerus Corp Stock Price and Quote
This article provides a comprehensive overview of Cerus Corp (CERS) stock, including its latest closing price, key financial metrics, performance indicators, and recent news. It also details analyst ratings and insider trading activities, offering a snapshot of the company's market position and investor sentiment.
Restricted-stock sales reported by issuer (NASDAQ: CERS)
Cerus Corp (NASDAQ: CERS) has reported multiple sales of restricted common stock by an affiliate, Vivek K Jayaraman, through a Form 144 SEC filing. The filing details transactions on May 1, 2026, March 13, 2026, and March 6, 2026, specifying the number of shares sold and their gross proceeds. This indicates a release of restricted shares into the market, which can be relevant for assessing potential dilution and market supply.
CERS News | CERUS CORP (NASDAQ:CERS)
This article provides recent news and analysis for Cerus Corp (NASDAQ:CERS), including stock performance and past financial results. It highlights a surge due to a strong Q1 beat and raised guidance, as well as a previous dip following mixed Q4 2025 results and a revenue miss. The current stock price is reported along with pre-market trading information.
Cerus Company Profile & Introduction
The Cerus Company Profile & Introduction was requested, however, the content of the document was not provided. To fulfill the request, the actual content of the company profile is needed.
Significant Cerus shareholder to oppose CEO and pay chair at June 2 vote
Bradley L. Radoff, a major shareholder in Cerus Corporation, announced his intention to vote against the re-election of CEO William Greenman and Compensation Committee Chair Ann Lucena at the upcoming June 2, 2026 annual meeting. Radoff cites negative returns, significant stock dilution, and concerns over Greenman's planned transition to Executive Chair as reasons for his opposition. He argues that the company has failed to create shareholder value and maintains a problematic classified Board structure.
Q1 2026 Cerus Corp Earnings Call Transcript
Cerus Corp reported a 24% increase in product revenue for Q1 2026, driven by strong global platelet franchise and U.S. ISC business, leading to raised full-year 2026 product revenue guidance. The company secured a multi-year contract with the French National Blood Service and achieved its eighth consecutive quarter of positive non-GAAP adjusted EBITDA. However, Cerus faces logistical challenges in the Middle East and a decrease in gross margin due to inflationary pressures and tariffs.
